Skip to main content

Table 2 PSA response and outcome after ADT with or without selective estrogen receptor modulators (n = 15)

From: Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial

  ADT (n = 5) TOPADT (n = 5) RAPADT (n = 5)
Follow-up period (median, range) 1169 (431―1631) 1653 (730―1983) 1570 (750―1883)
PSA nadir (ng/mL) ≥1 1 0 1
0.01–1.0 2 3 3
≤0.01 2 2 1
Biochemical recurrence No 2 5 3
Yes 3 0 2
Outcome Alive with disease 4 4 5
Died of PC 1 0 0
Died of other disease 0 1: Died of gastric cancer 0
Adverse event   Hot flush: 2 Hot flush: 3, Headache: 1 Hot flush: 3
  1. ADT androgen deprivation therapy including surgical or medical castration plus bicalutamide, TOPADT toremifene plus ADT, RAPADT raloxifene plus ADT, PC prostate cancer
\